von Ibrahim Alkatout ; Rudy Leon de Wilde ; Jörg Herrmann ; Rüdiger Klapdor ; Ivo Meinhold-Heerlein ; József Mészáros ; Alexander Mustea ; Peter Oppelt ; Julian Maria Pape ; Sebastian Daniel Schäfer ; Markus Wallwiener ; Bernhard Krämer
von Rong Fang ; Marco Düring ; Felix J. Bode ; Sebastian Stösser ; Julius Nicolai Meißner ; Peter Hermann ; Thomas Liman ; Christian H. Nolte ; Lucia Kerti ; Benno Ikenberg ; Kathleen Bernkopf ; Wenzel Glanz ; Daniel Janowitz ; Michael Wagner ; Katja Neumann ; Oliver Speck ; Emrah Düzel ; Benno Gesierich ; Anna Dewenter ; Annika Spottke ; Karin Waegemann ; Michael Görtler ; Silke Wunderlich ; Inga Zerr ; Gabor Petzold ; Matthias Endres ; Marios K. Georgakis ; Martin Dichgans
von Friederike A. Arlt ; Pia S. Sperber ; Regina von Rennenberg ; Pimrapat Gebert ; Bianca Teegen ; Marios K. Georgakis ; Rong Fang ; Anna Dewenter ; Michael Görtler ; Gabor Petzold ; Silke Wunderlich ; Inga Zerr ; Martin Dichgans ; Harald Prüß ; Matthias Endres
Thomas Liman; Christian H Nolte; Lucia Kerti; Tatjana Wittenberg; Jan Friedrich Scheitz; Alexander Heinrich Nave; Anna Kufner; Felix J Bode; Sebastian Stösser; Julius Nicolai Meißner; Taraneh Ebrahimi; Julia Nordsiek; Niklas Michael Beckonert; Peter Hermann; Matthias Schmitz; Stefan Goebel; Julia Schütte-Schmidt; Sabine Nuhn; Corinna Volpers; Peter Dechent; Matthias Bähr; Wenzel Glanz; Steffen Tiedt; Karin Waegemann; Daniel Janowitz; Benno Ikenberg; Kathleen Bermkopf; Christiane Huber; Michael Wagner; Katja Neumann; Annika Spottke; Tony Stöcker; Marco Dühring; Oliver Speck; Emrah Düzel; Peter Bartenstein
von Jürgen Beck ; Christian Fung ; Daniel Strbian ; Lukas Bütikofer ; Werner J. Z'Graggen ; Matthias F. Lang ; Seraina Beyeler ; Jan Gralla ; Florian Ringel ; Karl Schaller ; Nikolaus Plesnila ; Marcel Arnold ; Werner Hacke ; Peter Jüni ; Alexander David Mendelow ; Christian Stapf ; Rustam Al-Shahi Salman ; Jenny Bressan ; Stefanie Lerch ; Arsany Hakim ; Nicolas Martinez-Majander ; Anna Piippo-Karjalainen ; Peter Vajkoczy ; Stefan Wolf ; Gerrit A. Schubert ; Anke Höllig ; Michael Veldeman ; Roland Rölz ; Andreas Gruber ; Philip Rauch ; Dorothee Wachter ; Veit Rohde ; Thomas Kerz ; Eberhard Uhl ; Enea Thanasi ; Hagen B. Huttner ; Bernd Kallmünzer ; L. Jaap Kappelle ; Wolfgang Deinsberger ; Christian Roth ; Robin Lemmens ; Jan Leppert ; Jose L. Sanmillan ; Jonathan M. Coutinho ; Katharina Hackenberg ; Gernot Reimann ; Mikael Mazighi ; Claudio L. A. Bassetti ; Heinrich P. Mattle ; Andreas Raabe ; Urs Fischer
BACKGROUND: It is unknown whether decompressive craniectomy improves clinical outcome for people with spontaneous severe deep intracerebral haemorrhage. The SWITCH trial aimed to assess whether decompressive craniectomy plus best medical treatment in these patients improves outcome at 6 months compared to best medical treatment alone. METHODS: In this multicentre, randomised, open-label, assessor-blinded trial conducted in 42 stroke centres in Austria, Belgium, Finland, France, Germany, the Netherlands, Spain, Sweden, and Switzerland, adults (18-75 years) with a severe intracerebral haemorrhage involving the basal ganglia or thalamus were randomly assigned to receive either decompressive craniectomy plus best medical treatment or best medical treatment alone. The primary outcome was a score of 5-6 on the modified Rankin Scale (mRS) at 180 days, analysed in the intention-to-treat population. This trial is registered with ClincalTrials.gov, NCT02258919, and is completed. FINDINGS: SWITCH had to be stopped early due to lack of funding. Between Oct 6, 2014, and April 4, 2023, 201 individuals were randomly assigned and 197 gave delayed informed consent (96 decompressive craniectomy plus best medical treatment, 101 best medical treatment). 63 (32%) were women and 134 (68%) men, the median age was 61 years (IQR 51-68), and the median haematoma volume 57 mL (IQR 44-74). 42 (44%) of 95 participants assigned to decompressive craniectomy plus best medical treatment and 55 (58%) assigned to best medical treatment alone had an mRS of 5-6 at 180 days (adjusted risk ratio [aRR] 0·77, 95% CI 0·59 to 1·01, adjusted risk difference [aRD] -13%, 95% CI -26 to 0, p=0·057). In the per-protocol analysis, 36 (47%) of 77 participants in the decompressive craniectomy plus best medical treatment group and 44 (60%) of 73 in the best medical treatment alone group had an mRS of 5-6 (aRR 0·76, 95% CI 0·58 to 1·00, aRD -15%, 95% CI -28 to 0). Severe adverse events occurred in 42 (41%) of 103 participants receiving decompressive craniectomy plus best medical treatment and 41 (44%) of 94 receiving best medical treatment. INTERPRETATION: SWITCH provides weak evidence that decompressive craniectomy plus best medical treatment might be superior to best medical treatment alone in people with severe deep intracerebral haemorrhage. The results do not apply to intracerebral haemorrhage in other locations, and survival is associated with severe disability in both groups. FUNDING: Swiss National Science Foundation, Swiss Heart Foundation, Inselspital Stiftung, and Boehringer Ingelheim.
The lancet London [u.a.] : Elsevier, 1823 403(2024), 10442 vom: Juni, Seite 2395-2404 Online-Ressource
In this thesis we resolve generalized semi-classical operators geometrically by means of blow-up and construct quasimodes on the resolved spaces. The goal is to generalize the well-known methods for constructing WKB approximations for solutions of the Schrödinger equation to a wider class of operators P=P(x,h,d/dx). The central tool is the newly introduced Newton polygon of a semi-classical operator P, which is used to predict qualitative and quantitative statements about the existence of quasimodes. Moreover, we consider operators whose solutions of their induced eikonal equation have jumps of multiplicity. These are algorithmically resolved by chaining quasihomogeneous blow-ups, in the sense that we can construct sufficiently regular WKB-type quasimodes for the operator ß*P on the resolved space.
In dieser Dissertation werden verallgemeinerte, semi-klassische Operatoren geometrisch durch Blow-ups aufgelöst und anschließend Quasimoden auf den aufgelösten Räumen konstruiert. Das Ziel ist dabei die bekannten Methoden zur Konstruktion von WKB-Approximation von Lösungen der Schrödinger-Gleichung auf eine größere Klasse von Operatoren P=P(x,h,d/dx) zu verallgemeinern. Das zentrale Hilfsmittel ist dabei das neu eingeführte Newton Polygon eines semi-klassischen Operators P, welches genutzt wird um qualitative und quantitative Aussagen über die Existenz von Quasimoden vorherzusagen. Darüber hinaus betrachten wir Operatoren, dessen Lösungen der induzierten Eikonalgleichungen Multiplizitätssprünge aufweisen. Diese werden algorithmisch durch die Anwendung verketteter, quasihomogener Blow-ups aufgelöst, in dem Sinne, dass wir hinreichend reguläre Quasimoden von WKB-Art für den Operator ß*P auf dem aufgelösten Raum konstruieren können.
von Marcio Roberto Pie ; Fernanda S. Caron ; Thom Dallimore ; Helena J. R. Einzmann ; Peter Hietz ; Michael Kessler ; Flavio Nunes Ramos ; João Pedro Costa Elias ; Holger Kreft ; Thorsten Krömer ; Maria Judith Carmona Higuita ; Daniel Zuleta ; Giesta Machado ; André Luís de Gasper ; Gerhard Zotz ; Glenda Mendieta-Leiva ; Derio Antonio Jimenez-Lopez ; Alex Fernando Mendes ; Pedro Brancalion ; Sara Mortara ; Christopher Thomas Blum ; Mariana Victória Irume ; Nayely Martínez-Meléndez Nayely ; Ana Maria Benavides ; Carlos Renato Boelter ; Sven Batke
von Navid Farassat ; Daniel Böhringer ; Sebastian Küchlin ; Fanni E. Molnár ; Anne Schwietering ; Dorina Seger ; Martin J. Hug ; Anja-Birte Knöbel ; Sabine Schneider-Fuchs ; Gabriele Ihorst ; Bettina Kathrin Wabbels ; Christina Beisse ; Focke Ziemssen ; Frank Schüttauf ; Andrea Martina Hedergott ; Theresia Ring-Mangold ; Claudia Schuart ; Armin Wolf ; Stefanie Schmickler ; Julia Biermann ; Philipp Eberwein ; Karsten Hufendiek ; Anja Eckstein ; Gabriele Gusek-Schneider ; Michael Peter Schittkowski ; Thomas Lischka ; Wolf A. Lagrèze
Clinical trials; Medical ophthalmology; OPHTHALMOLOGY; Paediatric ophthalmology
Introduction Myopia is a major cause of degenerative eye disease and increases the risk of secondary visual impairment. Mitigating its progression therefore has great potential of clinically relevant benefit as shown by using highly diluted atropine eye drops in children of Asian origin. However, limited evidence is available regarding the efficacy and safety of low-dose atropine therapy in non-Asian populations. Hence, the Low-dose AtropIne for Myopia Control in Children (AIM) study will test the efficacy and safety of 0.02% atropine vs placebo in a German population. - Methods and analysis AIM is a national, multicentre, prospective, randomised, placebo-controlled, double-blind trial with two parallel arms. The primary objective is to assess the efficacy of atropine 0.02% eyedrops for myopia control in children of Caucasian origin. The primary outcome is the change in cycloplegic refraction after 1 year of treatment (D/year). Secondary and tertiary outcome measures comprise the change in axial length (mm/year) in children treated with 0.02% atropine compared with placebo, the myopic progression of participants treated with 0.01% compared with 0.02% atropine (D/year and mm/year), and the safety profile of both 0.02% and 0.01% atropine. Furthermore, the myopic progression 1 year after cessation of therapy with 0.02% atropine will be evaluated. Inclusion criteria are an age of 8-12 years and myopia of −1 D to −6 D with an estimated annual myopia progression of ≥0.5 D. After randomisation, patients will receive either atropine 0.02% (arm A) or placebo eye drops (arm B) in the first year of treatment. In the second year, they will continue to receive atropine 0.02% (arm A) or switch to atropine 0.01% (arm B). In the third year, they will switch to placebo (arm A) or continue with atropine 0.01% (arm B). To achieve a statistical power of 80%, the calculated sample size is 300. The trial has started in October 2021 with a planned recruitment period of 18 months. - Ethics and dissemination AIM has been approved by the Central Ethics Committee of the University Medical Center Freiburg (21-1106), local ethics committees of each participating centre and the German Federal Institute for Drugs and Medical Devices (61-3910-4044659). It complies with the Declaration of Helsinki, local laws and ICH-GCP. Results and underlying data from this trial will be disseminated through peer-reviewed publications and conference presentations. - Trial registration number NCT03865160.
BMJ open London : BMJ Publishing Group, 2011 13(2023), 4, Artikel-ID e068822, Seite 1-11 Online-Ressource
von Irena Maus ; Daniel Wibberg ; Peter Belmann ; Sarah Hahnke ; Liren Huang ; Cathrin Spröer ; Boyke Bunk ; Jochen Blom ; Alexander Sczyrba ; Alfred Pühler ; Michael Klocke ; Andreas Schlüter
